https://novapharmanews.com/us/news/global-ma-trends-health-industries-2026-outlook 2026-05-31T17:18:39.843Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Global M&A Trends in Health Industries: 2026 Outlook https://novapharmanews.com/uploads/articles/global-ma-trends-health-industries-2026-outlook.webp Global M&A Trends in Health Industries: 2026 Outlook https://novapharmanews.com/us/news/fda-decisions-q2-2026-drug-approvals 2026-05-31T19:48:43.314Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z 5 FDA Drug Approvals to Watch in 2026 https://novapharmanews.com/uploads/articles/fda-drug-approvals-2026.webp 5 FDA Drug Approvals to Watch in 2026 https://novapharmanews.com/us/news/resilience-reinvention-biotech-maturity 2026-05-31T17:18:18.570Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Resilience and Reinvention: Biotech’s Year of Maturity https://novapharmanews.com/uploads/articles/resilience-reinvention-biotech-maturity.webp Resilience and Reinvention: Biotech’s Year of Maturity https://novapharmanews.com/us/news/longeveron-q1-2026-financial-results-business-update 2026-05-31T18:18:39.452Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Longeveron Reports Q1 2026 Financial Results and Business Update https://novapharmanews.com/uploads/articles/longeveron-q1-2026-financial-results-business-update.webp Longeveron Reports Q1 2026 Financial Results and Business Update https://novapharmanews.com/us/news/chinese-pharma-innovators-global-expansion 2026-05-31T17:18:47.123Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Chinese Pharma Innovators Expand Globally with Innovative Deal Structures https://novapharmanews.com/uploads/articles/chinese-pharma-innovators-global-expansion.webp Chinese Pharma Innovators Expand Globally with Innovative Deal Structures https://novapharmanews.com/us/news/altrx-glp-1-review-2026-fda-updates-semaglutide 2026-05-31T18:58:32.529Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z altRx GLP-1 Review 2026: FDA Updates on Semaglutide semaglutide, GLP-1 https://novapharmanews.com/uploads/articles/altrx-glp-1-review-2026-fda-updates-semaglutide.webp altRx GLP-1 Review 2026: FDA Updates on Semaglutide https://novapharmanews.com/us/news/vir-astellas-240m-prostate-cancer-trials 2026-05-31T15:47:25.341Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Vir-Astellas Secures $240M for Prostate Cancer Trials prostate cancer https://novapharmanews.com/uploads/articles/vir-astellas-240m-prostate-cancer-trials.webp Vir-Astellas Secures $240M for Prostate Cancer Trials https://novapharmanews.com/us/news/china-approves-hernexeos-lung-cancer-treatment 2026-05-31T17:18:13.358Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z China Approves HERNEXEOS for Lung Cancer Treatment HERNEXEOS, oncology, lung cancer https://novapharmanews.com/uploads/articles/china-approves-hernexeos-lung-cancer-treatment.webp China Approves HERNEXEOS for Lung Cancer Treatment https://novapharmanews.com/us/news/pennsylvania-compounding-pharmacy-fda-warning-letter 2026-05-31T15:47:43.382Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Pennsylvania Compounding Pharmacy Receives FDA Warning Letter https://novapharmanews.com/uploads/articles/pennsylvania-compounding-pharmacy-fda-warning-letter.webp Pennsylvania Compounding Pharmacy Receives FDA Warning Letter https://novapharmanews.com/us/news/china-drug-development-oncology-us 2026-05-31T15:47:31.043Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z China’s Rise in Drug Development Looms Over U.S. Oncology Market oncology https://novapharmanews.com/uploads/articles/china-drug-development-oncology-us.webp China’s Rise in Drug Development Looms Over U.S. Oncology Market https://novapharmanews.com/us/news/jpm26-biotech-ma-insights-market-analysis 2026-05-31T17:18:03.859Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z JPM26: Biotech M&A Insights and Market Analysis https://novapharmanews.com/uploads/articles/jpm26-biotech-ma-insights-market-analysis.webp JPM26: Biotech M&A Insights and Market Analysis https://novapharmanews.com/us/news/wockhardt-us-fda-approval-zaynich 2026-05-31T19:00:59.475Z NovaPharmaNews en-US 2026-05-31T05:30:08.880Z Wockhardt Secures US FDA Approval for ZAYNICH: A Milestone for Indian Pharma ZAYNICH https://novapharmanews.com/uploads/articles/wockhardt-us-fda-approval-zaynich.webp Wockhardt Secures US FDA Approval for ZAYNICH: A Milestone for Indian Pharma https://novapharmanews.com/eu/news/arrowhead-pharmaceuticals-positive-clinical-data-eas-congress 2026-05-31T15:46:40.298Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Arrowhead Pharmaceuticals Unveils Positive Clinical Data at EAS Congress cardiometabolic disorders https://novapharmanews.com/uploads/articles/arrowhead-pharmaceuticals-positive-clinical-data-eas-congress.webp Arrowhead Pharmaceuticals Unveils Positive Clinical Data at EAS Congress https://novapharmanews.com/us/news/fda-blueprint-regulatory-risk-animal-testing-alternatives 2026-05-31T08:02:53.289Z NovaPharmaNews en-US 2026-05-31T05:30:01.835Z FDA Blueprint to Reduce Regulatory Risks for Animal Testing Alternatives https://novapharmanews.com/uploads/articles/fda-blueprint-regulatory-risk-animal-testing-alternatives.webp FDA Blueprint to Reduce Regulatory Risks for Animal Testing Alternatives https://novapharmanews.com/us/news/lilly-38b-investment-infectious-disease-portfolio 2026-05-31T17:18:10.735Z NovaPharmaNews en-US 2026-05-31T05:30:01.835Z Eli Lilly's $3.8B Investment in Infectious Disease Portfolio infectious diseases https://novapharmanews.com/uploads/articles/lilly-38b-investment-infectious-disease-portfolio.webp Eli Lilly's $3.8B Investment in Infectious Disease Portfolio https://novapharmanews.com/us/news/fda-new-guidance-ai-regulatory-restraint 2026-05-31T08:40:53.899Z NovaPharmaNews en-US 2026-05-31T05:30:01.835Z FDA's New Guidance on AI: Regulatory Restraint Explained https://novapharmanews.com/uploads/articles/fda-new-guidance-ai-regulatory-restraint.webp FDA's New Guidance on AI: Regulatory Restraint Explained https://novapharmanews.com/us/news/fda-device-guidance-agenda-2026 2026-05-31T08:02:36.207Z NovaPharmaNews en-US 2026-05-31T05:30:01.835Z FDA Device Guidance Agenda: Key Regulatory Updates for 2026 https://novapharmanews.com/uploads/articles/fda-device-guidance-agenda-2026.webp FDA Device Guidance Agenda: Key Regulatory Updates for 2026 https://novapharmanews.com/eu/news/owkin-astrazeneca-ai-collaboration-drug-research 2026-05-31T17:18:21.885Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Owkin and AstraZeneca Enhance AI Collaboration for Drug Research https://novapharmanews.com/uploads/articles/owkin-astrazeneca-ai-collaboration-drug-research.webp Owkin and AstraZeneca Enhance AI Collaboration for Drug Research https://novapharmanews.com/eu/news/esmo-asia-nadia-harbeck-oncology-advances 2026-05-31T17:18:34.877Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Insights from ESMO Asia: Nadia Harbeck on Oncology Advances oncology https://novapharmanews.com/uploads/articles/esmo-asia-nadia-harbeck-oncology-advances.webp Insights from ESMO Asia: Nadia Harbeck on Oncology Advances https://novapharmanews.com/eu/news/cancer-therapy-ost-her2-2026-ema-call 2026-05-31T17:18:46.185Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data OST-HER2, cancer https://novapharmanews.com/uploads/articles/cancer-therapy-ost-her2-2026-ema-call.webp Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data https://novapharmanews.com/eu/news/innovent-biologics-shares-surge-pfizer-deal 2026-05-31T18:57:59.227Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Innovent Biologics Shares Surge 10% Following Pfizer Deal https://novapharmanews.com/uploads/articles/innovent-biologics-shares-surge-pfizer-deal.webp Innovent Biologics Shares Surge 10% Following Pfizer Deal https://novapharmanews.com/eu/news/innovent-pfizer-cancer-drug-deal 2026-05-31T19:47:44.943Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Innovent Biologics and Pfizer's $10.5 Billion Cancer Drug Deal cancer https://novapharmanews.com/uploads/articles/innovent-pfizer-cancer-drug-deal.webp Innovent Biologics and Pfizer's $10.5 Billion Cancer Drug Deal https://novapharmanews.com/eu/news/privosegtor-ema-prime-optic-neuritis 2026-05-31T18:58:01.647Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z Privosegtor Secures EMA PRIME Designation for Optic Neuritis optic neuritis https://novapharmanews.com/uploads/articles/privosegtor-ema-prime-optic-neuritis.webp Privosegtor Secures EMA PRIME Designation for Optic Neuritis https://novapharmanews.com/eu/news/25-posts-not-to-miss-elcc-2026-oncology 2026-05-31T18:57:40.570Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z 25 Posts Not To Miss From ELCC 2026: Oncology Insights oncology https://novapharmanews.com/uploads/articles/25-posts-not-to-miss-elcc-2026-oncology.webp 25 Posts Not To Miss From ELCC 2026: Oncology Insights https://novapharmanews.com/eu/news/chmp-negative-stance-acadia-rett-syndrome-drug 2026-05-31T15:26:48.448Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z CHMP's Negative Stance on Acadia's Rett Syndrome Drug Acadia, Rett syndrome https://novapharmanews.com/uploads/articles/chmp-negative-stance-acadia-rett-syndrome-drug.webp CHMP's Negative Stance on Acadia's Rett Syndrome Drug https://novapharmanews.com/eu/news/lenz-therapeutics-vizz-ema-presbyopia 2026-05-31T15:46:55.793Z NovaPharmaNews en-GB 2026-05-31T05:30:01.835Z LENZ Therapeutics Submits VIZZ® Application to EMA for Presbyopia VIZZ, Presbyopia https://novapharmanews.com/uploads/articles/lenz-therapeutics-vizz-ema-presbyopia.webp LENZ Therapeutics Submits VIZZ® Application to EMA for Presbyopia https://novapharmanews.com/apac/news/biomarkers-digital-technologies-oncology-asia-2026 2026-05-31T15:47:21.413Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z Biomarkers and Digital Technologies Transforming Oncology in Asia oncology https://novapharmanews.com/uploads/articles/biomarkers-digital-technologies-oncology-asia-2026.webp Biomarkers and Digital Technologies Transforming Oncology in Asia https://novapharmanews.com/apac/news/smarter-medical-devices-ecosystem-india-regulatory-updates 2026-05-31T20:17:15.769Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z Building a Smarter Medical Devices Ecosystem in India: Regulatory Updates https://novapharmanews.com/uploads/articles/smarter-medical-devices-ecosystem-india-regulatory-updates.webp Building a Smarter Medical Devices Ecosystem in India: Regulatory Updates https://novapharmanews.com/apac/news/uk-clinical-trials-oncology-impact 2026-05-31T16:17:34.506Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z UK Clinical Trials in Oncology: Actions Driving Impact oncology https://novapharmanews.com/uploads/articles/uk-clinical-trials-oncology-impact.webp UK Clinical Trials in Oncology: Actions Driving Impact https://novapharmanews.com/apac/news/innovative-oncology-pharma-china 2026-05-31T15:47:00.171Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z Innovative Oncology Pharma Companies in China: A Look Ahead oncology https://novapharmanews.com/uploads/articles/innovative-oncology-pharma-china.webp Innovative Oncology Pharma Companies in China: A Look Ahead https://novapharmanews.com/apac/news/asia-pacific-eclinical-solutions-market-report-2025-2030 2026-05-31T20:27:41.769Z NovaPharmaNews en-AU 2026-05-31T05:30:01.835Z Asia Pacific eClinical Solutions Market Report 2025-2030: Key Insights https://novapharmanews.com/uploads/articles/asia-pacific-eclinical-solutions-market-report-2025-2030.webp Asia Pacific eClinical Solutions Market Report 2025-2030: Key Insights https://novapharmanews.com/eu/news/chmp-may-2026-output-shift-european-drug-development 2026-05-31T17:58:46.419Z NovaPharmaNews en-GB 2026-05-30T13:14:56.236Z CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/uploads/articles/chmp-may-2026-drug-approvals.webp CHMP May 2026 Output: A New Era in Drug Approvals https://novapharmanews.com/us/news/lunai-bioworks-brainstorm-therapeutics-ai-collaboration 2026-05-31T15:37:59.473Z NovaPharmaNews en-US 2026-05-30T13:14:56.236Z Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy Parkinson's disease, Rare Epilepsy https://novapharmanews.com/uploads/articles/lunai-bioworks-brainstorm-therapeutics-ai-collaboration.webp Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy https://novapharmanews.com/us/news/pharma-ma-boom-2026-market-analysis 2026-05-31T20:03:15.617Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Pharma M&A Set to Boom in 2026: Market Analysis https://novapharmanews.com/uploads/articles/pharma-ma-boom-2026-market-analysis.webp Pharma M&A Set to Boom in 2026: Market Analysis https://novapharmanews.com/us/news/ai-brain-organoids-parkinsons-rare-epilepsy-regulatory-updates 2026-05-31T13:33:11.951Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z AI and Brain Organoids Combat Parkinson's and Rare Epilepsy Parkinson's disease, Rare Epilepsy https://novapharmanews.com/uploads/articles/ai-brain-organoids-parkinsons-rare-epilepsy-regulatory-updates.webp AI and Brain Organoids Combat Parkinson's and Rare Epilepsy https://novapharmanews.com/us/news/longeveron-stockholder-letter-corporate-strategy-2026-goals 2026-05-31T17:18:25.299Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Longeveron Stockholder Letter Highlights Corporate Strategy and 2026 Goals https://novapharmanews.com/uploads/articles/longeveron-stockholder-letter-corporate-strategy-2026-goals.webp Longeveron Stockholder Letter Highlights Corporate Strategy and 2026 Goals https://novapharmanews.com/us/news/ai-breast-cancer-risk-prediction-tool-fda-approval 2026-05-31T18:58:17.126Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z AI Breast Cancer Risk Prediction Tool Gains FDA Approval oncology, breast cancer https://novapharmanews.com/uploads/articles/ai-breast-cancer-risk-prediction-tool-fda-approval.webp AI Breast Cancer Risk Prediction Tool Gains FDA Approval https://novapharmanews.com/us/news/pharmtech-regulatory-roundup-may-2026-drug-approvals 2026-05-31T17:17:55.646Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z PharmTech’s Regulatory Roundup for May 2026: Drug Approvals https://novapharmanews.com/uploads/articles/pharmtech-regulatory-roundup-may-2026-drug-approvals.webp PharmTech’s Regulatory Roundup for May 2026: Drug Approvals https://novapharmanews.com/us/news/regeneron-fda-approval-neurosensory-gene-therapy 2026-05-31T17:55:02.938Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Regeneron Secures FDA Approval for Pioneering Neurosensory Gene Therapy gene therapy https://novapharmanews.com/uploads/articles/regeneron-fda-approval-neurosensory-gene-therapy.webp Regeneron Secures FDA Approval for Pioneering Neurosensory Gene Therapy https://novapharmanews.com/us/news/life-sciences-dealmaking-momentum-strategic-pressures 2026-05-31T13:41:07.635Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Life Sciences Dealmaking Gains Momentum Amid Strategic Pressures https://novapharmanews.com/uploads/articles/life-sciences-dealmaking-momentum-strategic-pressures.webp Life Sciences Dealmaking Gains Momentum Amid Strategic Pressures https://novapharmanews.com/us/news/bizengri-fda-national-priority-rare-bile-duct-cancer 2026-05-31T17:17:45.498Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Bizengri Receives FDA National Priority Nod for Rare Bile Duct Cancer Bizengri, rare bile duct cancer https://novapharmanews.com/uploads/articles/bizengri-fda-national-priority-rare-bile-duct-cancer.webp Bizengri Receives FDA National Priority Nod for Rare Bile Duct Cancer https://novapharmanews.com/us/news/big-pharma-biotech-assets-patent-cliff 2026-05-31T15:46:57.363Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Big Pharma's Race for Biotech Assets Amid $170 Billion Patent Cliff https://novapharmanews.com/uploads/articles/big-pharma-biotech-assets-patent-cliff.webp Big Pharma's Race for Biotech Assets Amid $170 Billion Patent Cliff https://novapharmanews.com/us/news/fda-commissioner-resignation-drug-approvals 2026-05-31T13:31:40.128Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z FDA Commissioner Resignation and Its Impact on Drug Approvals https://novapharmanews.com/uploads/articles/fda-commissioner-resignation-drug-approvals.webp FDA Commissioner Resignation and Its Impact on Drug Approvals https://novapharmanews.com/us/news/vir-biotechnology-stock-board-reshuffle-governance-votes 2026-05-31T20:03:02.714Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/uploads/articles/vir-biotechnology-stock-board-reshuffle-governance-votes.webp Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM https://novapharmanews.com/us/news/regulatory-actions-may-2026 2026-05-31T15:59:06.460Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Regulatory Actions in May 2026: Key Updates for Pharma https://novapharmanews.com/uploads/articles/regulatory-actions-may-2026.webp Regulatory Actions in May 2026: Key Updates for Pharma https://novapharmanews.com/us/news/pfizer-innovent-deal-global-drug-development-oncology 2026-05-31T18:58:47.349Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Pfizer-Innovent Deal: A New Model for Global Drug Development in Oncology oncology https://novapharmanews.com/uploads/articles/pfizer-innovent-deal-global-drug-development-oncology.webp Pfizer-Innovent Deal: A New Model for Global Drug Development in Oncology https://novapharmanews.com/us/news/editas-medicine-inc-stock-quiet-trading-clinical-trials 2026-05-31T13:32:41.095Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Editas Medicine Inc Stock: Quiet Trading Ahead of Clinical Trials https://novapharmanews.com/uploads/articles/editas-medicine-inc-stock-quiet-trading-clinical-trials.webp Editas Medicine Inc Stock: Quiet Trading Ahead of Clinical Trials https://novapharmanews.com/us/news/big-pharma-ma-spree-march-ipo-drought 2026-05-31T13:33:17.666Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z Big Pharma's M&A Spree and the March IPO Drought: An Analysis https://novapharmanews.com/uploads/articles/big-pharma-ma-spree-march-ipo-drought.webp Big Pharma's M&A Spree and the March IPO Drought: An Analysis https://novapharmanews.com/us/news/states-confront-medical-chatbots-oversight-fda-inaction 2026-05-31T16:52:57.920Z NovaPharmaNews en-US 2026-05-30T13:14:44.366Z States Confront Medical Chatbots Oversight Amid FDA Inaction https://novapharmanews.com/uploads/articles/states-confront-medical-chatbots-oversight-fda-inaction.webp States Confront Medical Chatbots Oversight Amid FDA Inaction https://novapharmanews.com/eu/news/prac-meeting-highlights-may-2026 2026-05-31T19:07:54.238Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z PRAC Meeting Highlights: Regulatory Updates from May 2026 https://novapharmanews.com/uploads/articles/prac-meeting-highlights-may-2026.webp PRAC Meeting Highlights: Regulatory Updates from May 2026 https://novapharmanews.com/eu/news/critical-medicines-act-council-parliament-deal 2026-05-31T16:30:10.216Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Critical Medicines Act: Council and Parliament Reach Provisional Deal https://novapharmanews.com/uploads/articles/critical-medicines-act-council-parliament-deal.webp Critical Medicines Act: Council and Parliament Reach Provisional Deal https://novapharmanews.com/eu/news/imfinzi-fda-approval-bladder-cancer 2026-05-31T15:46:31.145Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Imfinzi Receives FDA Approval for Bladder Cancer Treatment Imfinzi, oncology, bladder cancer https://novapharmanews.com/uploads/articles/imfinzi-fda-approval-bladder-cancer.webp Imfinzi Receives FDA Approval for Bladder Cancer Treatment https://novapharmanews.com/eu/news/pfizer-innovent-105bn-adc-oncology-partnership 2026-05-31T18:57:55.960Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Join Forces for $10.5bn ADC Oncology Partnership oncology https://novapharmanews.com/uploads/articles/pfizer-innovent-105bn-adc-oncology-partnership.webp Pfizer and Innovent Join Forces for $10.5bn ADC Oncology Partnership https://novapharmanews.com/apac/news/regulatory-round-up-drug-approvals-april-20-2026 2026-05-31T18:23:43.643Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Regulatory Round-Up: Drug Approvals on April 20, 2026 https://novapharmanews.com/uploads/articles/regulatory-round-up-drug-approvals-april-20-2026.webp Regulatory Round-Up: Drug Approvals on April 20, 2026 https://novapharmanews.com/apac/news/premia-lind-ai-clinical-trial-screening-asia-pacific 2026-05-31T15:39:58.752Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific https://novapharmanews.com/uploads/articles/premia-lind-ai-clinical-trial-screening-asia-pacific.webp PREMIA and Lind Expand AI-Powered Clinical Trial Screening Across Asia-Pacific https://novapharmanews.com/apac/news/cell-gene-therapy-approvals-china-regulatory-updates 2026-05-31T19:31:37.064Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Cell and Gene Therapy Approvals in China: Latest Regulatory Updates gene therapy https://novapharmanews.com/uploads/articles/cell-gene-therapy-approvals-china-regulatory-updates.webp Cell and Gene Therapy Approvals in China: Latest Regulatory Updates https://novapharmanews.com/apac/news/onconic-therapeutics-jakubo-phase-3-clinical-trials-china 2026-05-31T13:32:57.950Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China https://novapharmanews.com/uploads/articles/onconic-therapeutics-jakubo-phase-3-clinical-trials-china.webp Onconic Therapeutics' Jakubo Enters Phase 3 Clinical Trials in China https://novapharmanews.com/apac/news/innovent-biologics-pfizer-10-5b-oncology-partnership 2026-05-31T20:24:00.792Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Innovent Biologics and Pfizer: A $10.5B Oncology Partnership oncology, cancer https://novapharmanews.com/uploads/articles/innovent-biologics-pfizer-10-5b-oncology-partnership.webp Innovent Biologics and Pfizer: A $10.5B Oncology Partnership https://novapharmanews.com/eu/news/imfinzi-approval-bladder-cancer 2026-05-31T15:46:25.388Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer durvalumab, Imfinzi, oncology, non-muscle-invasive bladder cancer https://novapharmanews.com/uploads/articles/imfinzi-approval-bladder-cancer.webp IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer https://novapharmanews.com/apac/news/clinical-trials-market-oncology-2034 2026-05-31T13:33:05.802Z NovaPharmaNews en-AU 2026-05-30T13:14:36.494Z Clinical Trials Market in Oncology: Size and Growth Insights for 2034 oncology https://novapharmanews.com/uploads/articles/clinical-trials-market-oncology-2034.webp Clinical Trials Market in Oncology: Size and Growth Insights for 2034 https://novapharmanews.com/eu/news/pfizer-innovent-cancer-drug-alliance 2026-05-31T13:32:26.320Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Form $10.5 Billion Cancer Drug Alliance oncology, cancer https://novapharmanews.com/uploads/articles/pfizer-innovent-cancer-drug-alliance.webp Pfizer and Innovent Form $10.5 Billion Cancer Drug Alliance https://novapharmanews.com/eu/news/2026-cell-therapy-regulatory-landscape 2026-05-31T17:23:51.563Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Navigating the 2026 Cell Therapy Regulatory Landscape cell therapy https://novapharmanews.com/uploads/articles/2026-cell-therapy-regulatory-landscape.webp Navigating the 2026 Cell Therapy Regulatory Landscape https://novapharmanews.com/eu/news/merz-therapeutics-kvvit-inbrija-agreement 2026-05-31T18:23:51.744Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® INBRIJA, levodopa https://novapharmanews.com/uploads/articles/merz-therapeutics-kvvit-inbrija-agreement.webp Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® https://novapharmanews.com/eu/news/italy-fourth-europe-clinical-research-enrollment 2026-05-31T18:18:57.457Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Italy Ranks Fourth in Europe for Clinical Research but Lags in Enrollment Speed https://novapharmanews.com/uploads/articles/italy-fourth-europe-clinical-research-enrollment.webp Italy Ranks Fourth in Europe for Clinical Research but Lags in Enrollment Speed https://novapharmanews.com/eu/news/esmo-2025-preview-astra-daiichi-gilead 2026-05-31T18:57:45.682Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z ESMO 2025 Preview: Astra and Daiichi vs. Gilead oncology https://novapharmanews.com/uploads/articles/esmo-2025-preview-astra-daiichi-gilead.webp ESMO 2025 Preview: Astra and Daiichi vs. Gilead https://novapharmanews.com/eu/news/pfizer-innovent-10-5bn-oncology-deal 2026-05-31T13:31:50.840Z NovaPharmaNews en-GB 2026-05-30T13:14:36.494Z Pfizer and Innovent Biologics' $10.5bn Oncology Deal: What It Means oncology, cancer https://novapharmanews.com/uploads/articles/pfizer-innovent-10-5bn-oncology-deal.webp Pfizer and Innovent Biologics' $10.5bn Oncology Deal: What It Means